Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
79.78 EUR | -1.15% | -2.50% | +32.64% |
Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Dividend / Share (DPS) - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- ROVI Stock
- Revisions Laboratorios Farmaceuticos Rovi, S.A.